Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy
Nearly half of patients prescribed BA failed to receive therapy due to a combination of payer rejections and prescription abandonment. Arduous utilization management criteria or high OOP costs put patients at high risk for failure of therapy initiation.
Authors
- Kristin Gillard
- Evelyn Sarnes
- Anand Gupta (ORCID: https://orcid.org/0000-0002-7223-7360)
- Ann Marie Návar (ORCID: https://orcid.org/0000-0002-6197-9860)
- Eric David Peterson (ORCID: https://orcid.org/0000-0002-5415-4721)
- Jimin Hwang
Institutions
- Esperion Therapeutics (United States) (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-02-08
- DOI
- https://doi.org/10.1016/j.ajpc.2025.100940
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Esperion Therapeutics